Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I-Cheng Lee

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Therapeutic Advances in Medical Oncology|June 1, 2022
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinomaKuo-Wei Huang, Pei-Chang Lee, Yee Chao, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2024
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic AreasYi-Ping Hung, Pei-Chang Lee, Yen-Hwa Chang, et al.
American Journal of Cancer Research|August 6, 2021
Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAgI-Cheng Lee, Hao-Jan Lei, Gar-Yang Chau, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2019
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinomaI-Cheng Lee, Ya-Wen Hung, Chien-An Liu, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 27, 2011
Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis BI-Cheng Lee, Yi-Hsiang Huang, Che-Chang Chan, et al.
Journal of Hepatocellular Carcinoma|November 26, 2024
Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal AblationKuo-Cheng Wu, I-Cheng Lee, Chien-An Liu, et al.
Journal for Immunotherapy of Cancer|June 23, 2022
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinomaPei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2024
Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablationKuo-Cheng Wu, I-Cheng Lee, Chen-Ta Chi, et al.
American Journal of Cancer Research|December 7, 2021
Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resectionKuo-Cheng Wu, I-Cheng Lee, Chen-Ta Chi, et al.
Hepatology (Baltimore, Md.)|June 30, 2025
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapyPei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Medical Oncology|June 1, 2022
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinomaKuo-Wei Huang, Pei-Chang Lee, Yee Chao, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2024
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic AreasYi-Ping Hung, Pei-Chang Lee, Yen-Hwa Chang, et al.
American Journal of Cancer Research|August 6, 2021
Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAgI-Cheng Lee, Hao-Jan Lei, Gar-Yang Chau, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2019
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinomaI-Cheng Lee, Ya-Wen Hung, Chien-An Liu, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 27, 2011
Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis BI-Cheng Lee, Yi-Hsiang Huang, Che-Chang Chan, et al.
Journal of Hepatocellular Carcinoma|November 26, 2024
Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal AblationKuo-Cheng Wu, I-Cheng Lee, Chien-An Liu, et al.
Journal for Immunotherapy of Cancer|June 23, 2022
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinomaPei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2024
Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablationKuo-Cheng Wu, I-Cheng Lee, Chen-Ta Chi, et al.
American Journal of Cancer Research|December 7, 2021
Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resectionKuo-Cheng Wu, I-Cheng Lee, Chen-Ta Chi, et al.
Hepatology (Baltimore, Md.)|June 30, 2025
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapyPei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, et al.
Pageof 7